Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 17s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

Neonatal Hypoxic-Ischemic Encephalopathy: Advances in Therapeutic Hypothermia and Biomaker Research

Gayatri Katole[1], Suresh Kumar Gautam[2], Archana Shaha[3], Amol Uttamrao Borade[4], Ajay Kharche[5], Deepak Panjwani[6], Jai Narayan Mishra[7], Basavaraj H[*8]

[1]Associate Professor, Nagpur College of Pharmacy, Wanadongri, Nagpur 441110

[2]Associate Professor, Department of Biochemistry. Ananta Institute of Medical Sciences, NH-8, Rajsamand (Rajasthan) 313202,

Email ID: sugotam@gmail.com

[3]Assistant Professor, School of Pharmacy, Vishwakarma University, Pune, Kondhwa 411048

Email ID: archana.shaha@gmail.com

[4]Assistant Professor, Oriental College of Pharmacy, Sanpada (W), Navi Mumbai- 400705

[5]Assistant Professor, Oriental college of Pharmacy, Sanpada, Navi Mumbai,

Email ID: ajay.kharche@ocp.edu.in

[6]Assistant professor, Oriental College of Pharmacy Sanpada, Navi Mumbai,

Email ID: deepakpanjwani19@gmail.com

[7]Director, Kailash institute of pharmacy and management,Gida , Gorakhpur,

Email ID: Jai.jai1982@rediffmail.com

[8]Assistant Professor, Government College of Pharmacy, Banglore;

Email ID: basavarajhulkoti@gmail.com

***Corresponding Author:**

Basavaraj H;

Email ID: basavarajhulkoti@gmail.com

Cite this paper as: Gayatri Katole, Suresh Kumar Gautam, Archana Shaha, Amol Uttamrao Borade, Ajay Kharche, Deepak Panjwani, Jai Narayan Mishra, Basavaraj H, (2025) Neonatal Hypoxic-Ischemic Encephalopathy: Advances in Therapeutic Hypothermia and Biomaker Research. *Journal of Neonatal Surgery*, 14 (17s), 15-22.

ABSTRACT

Neonatal hypoxic-ischemic encephalopathy (HIE) is a serious condition resulting from insufficient oxygen and blood flow to the neonatal brain, leading to significant morbidity and mortality worldwide. Therapeutic hypothermia (TH) remains the only established treatment, offering neuroprotection by reducing cerebral metabolism, excitotoxicity, and inflammation, thereby improving survival and neurological outcomes. However, despite its benefits, a substantial proportion of infants treated with TH still experience death or long-term neurodevelopmental disabilities, highlighting the need for optimized therapies and adjunctive treatments. Recent advances have focused on understanding the complex pathophysiology of HIE, including phases of primary and secondary energy failure, oxidative stress, and neuroinflammation, which are critical for guiding intervention timing and development. Concurrently, biomarker research is rapidly evolving to identify reliable indicators of brain injury severity and progression, with promising candidates including neuroproteins, microRNAs, and inflammatory mediators. These biomarkers aim to enable early diagnosis, prognostication, and personalized treatment strategies. This review summarizes current therapeutic hypothermia protocols, explores novel adjunct therapies under clinical evaluation, and highlights emerging biomarker discoveries that hold potential to transform the management and outcomes of neonatal HIE. Further research and clinical trials are essential to improve neuroprotection and reduce the long-term impacts of HIE.

Keywords: *Antioxidants, Biomarkers, Encephalopathy, Hypoxia, Inflammation, Magnetic Resonance Imaging, Neonatal Brain Injury, Neurodevelopment, Oxidative Stress, Therapeutic Hypothermia, Urinary Biomarkers, White Matter*.

1. INTRODUCTION

A. Overview of Neonatal Hypoxic-Ischemic Encephalopathy (HIE)

Neonatal Hypoxic-Ischemic Encephalopathy (HIE) is a serious brain injury caused by oxygen deprivation and limited blood

flow to a newborn's brain, typically during labor or delivery. It represents a major cause of neonatal mortality and long-term neurological disabilities such as cerebral palsy, epilepsy, and cognitive impairments. HIE affects approximately 1 to 8 per 1,000 live births globally, with a higher prevalence in low-resource settings. This condition is a medical emergency requiring rapid diagnosis and intervention to prevent irreversible brain damage. Understanding HIE is crucial for improving outcomes and developing targeted therapies, especially in critical care neonatology.

B. Etiology and Pathophysiology of HIE

The etiology of HIE is multifactorial, including conditions such as placental abruption, uterine rupture, umbilical cord accidents, or maternal hypotension. These events can lead to impaired oxygen delivery and reduced cerebral perfusion. The resulting pathophysiology involves a biphasic injury process: primary energy failure during the hypoxic event and secondary injury due to reperfusion and inflammation. Excitotoxicity, oxidative stress, and apoptosis are key mechanisms contributing to neuronal injury. This complex cascade affects various brain regions, particularly the basal ganglia, thalamus, and cortex. Understanding these mechanisms is critical for devising therapeutic interventions like hypothermia and the exploration of neuroprotective agents.

C. Epidemiological Insights

Epidemiological data on HIE reveal significant disparities between high- and low-income countries. In high-resource settings, the incidence is about 1–3 per 1,000 live births, whereas in low-resource regions, it may reach up to 10 per 1,000. Factors such as lack of prenatal care, inadequate labor monitoring, and limited neonatal intensive care contribute to higher risks. Additionally, socio-economic status, maternal health, and access to emergency obstetric services affect incidence and outcomes. Understanding epidemiological patterns helps in identifying at-risk populations, improving perinatal care policies, and guiding the implementation of therapeutic strategies, such as therapeutic hypothermia, in diverse clinical environments.

D. Clinical Presentation and Diagnosis

Neonates with HIE typically present with altered consciousness, hypotonia, poor reflexes, abnormal respiration, and seizures. Diagnosis relies on a combination of clinical assessment and diagnostic tools. The Sarnat and Sarnat staging system is widely used to classify the severity into mild, moderate, or severe based on neurological function.



Fig 1: Diagnostics Tests for Hypoxic-Ischemic Encephalopathy

Supportive tests include EEG, MRI, cranial ultrasound, and biochemical markers like lactate. Early and accurate diagnosis is crucial for initiating timely therapeutic hypothermia and improving prognosis. Prompt identification also aids in selecting appropriate care levels and in counseling families about possible outcomes and long-term developmental support needs.

E. Current Management Strategies for HIE

Traditional management of HIE includes supportive care aimed at maintaining physiological stability: adequate oxygenation, ventilation, fluid balance, and seizure control. Anticonvulsants like phenobarbital are used to manage neonatal seizures. Although supportive care mitigates some acute complications, it does not halt the underlying brain injury. Recently, therapeutic hypothermia has emerged as the standard neuroprotective intervention. However, in many low-resource settings, such advanced care is not readily available, and management remains limited to symptomatic treatment. There is a growing need to expand access to comprehensive care and integrate novel therapeutic strategies to reduce morbidity and mortality associated with HIE.

F. Introduction to Therapeutic Hypothermia (TH)

Therapeutic Hypothermia (TH) is a breakthrough treatment that involves lowering the core body temperature of infants diagnosed with moderate to severe HIE to 33–34°C for 72 hours. This method has been shown to reduce the risk of death and long-term disability when initiated within six hours of birth.



Fig 2: Unveiling the Multifaced Effects of Therapeutic Hypothermia

TH works by slowing metabolic processes and reducing brain inflammation, oxidative stress, and apoptosis. It is now a standard of care in many neonatal intensive care units globally. The development and implementation of TH have significantly improved outcomes for affected infants, though challenges remain in its application, especially in resource-poor settings.

G. Mechanisms of Action of Therapeutic Hypothermia

Therapeutic hypothermia acts at multiple levels of the hypoxic-ischemic injury cascade. It reduces cerebral metabolism, thereby decreasing the demand for oxygen and glucose. Hypothermia attenuates glutamate excitotoxicity, limits free radical production, and inhibits apoptosis by modulating gene expression and mitochondrial function. It also reduces inflammation by affecting microglial activation and cytokine release. These neuroprotective effects help preserve brain structure and function. However, the therapeutic window is narrow, requiring initiation within six hours after birth. Ongoing research focuses on enhancing these mechanisms with adjunct therapies, including pharmacologic agents and stem cell-based treatments to further reduce neurological damage.

H. Challenges and Limitations of Therapeutic Hypothermia

While therapeutic hypothermia has revolutionized HIE management, it is not without limitations. Only about 50% of treated infants benefit fully, with many still experiencing neurodevelopmental deficits. Efficacy may be influenced by factors such as timing of initiation, severity of brain injury, and comorbidities. In low-resource settings, TH is often unavailable due to lack of equipment, training, or neonatal intensive care infrastructure. Additionally, the procedure may cause complications like hypotension, bradycardia, or coagulopathies. These challenges highlight the need for improved access, more precise patient selection, and adjunct therapies to enhance outcomes and extend the benefits of TH to more infants.

I. Emergence of Biomarkers in HIE Diagnosis and Prognosis

Biomarkers are gaining prominence in the early diagnosis and prognosis of HIE. These include biochemical markers (e.g., S100B, NSE, lactate), neuroimaging indicators (e.g., diffusion-weighted MRI), electrophysiological patterns (e.g., aEEG), and genetic or proteomic profiles. Biomarkers can help identify at-risk neonates, monitor disease progression, and predict long-term outcomes. Integrating biomarkers with therapeutic hypothermia could enable personalized treatment and optimize the therapeutic window. Research is ongoing to validate reliable, cost-effective biomarkers that can be used even in resource-limited settings. The development of such tools holds promise for advancing neonatal neurocritical care and tailoring interventions based on individual risk profiles.

J. Need for Further Research and Advancements

Despite significant progress, HIE remains a leading cause of neonatal mortality and long-term disability. Current therapies like therapeutic hypothermia are not universally effective and are limited by practical constraints. There is an urgent need for continued research to understand the complex molecular mechanisms of brain injury and recovery, discover novel biomarkers for early diagnosis, and develop adjunct or alternative therapies. Future advancements may include stem cell

therapy, nanomedicine, gene therapy, and pharmacologic neuroprotectants. Collaborative global efforts are essential to ensure that new innovations are accessible, affordable, and scalable, especially in underserved regions with high HIE burden.

2. LITERATURE REVIEW

Therapeutic hypothermia (TH) has emerged as a cornerstone in the management of neonatal hypoxic-ischemic encephalopathy (HIE), significantly reducing mortality and neurodevelopmental impairment in affected neonates [6][8]. Studies have shown that TH not only offers neuroprotection but may also have systemic benefits. For instance, one study reported reduced hepatic injury in neonates undergoing TH, evidenced by lower alanine aminotransferase (ALT) levels and delayed C-reactive protein (CRP) responses [1]. The neuroprotective effects of TH are further supported by findings from biomarker research. Elevated levels of interleukin-6 (IL-6), neuron-specific enolase (NSE), and glial fibrillary acidic protein (GFAP) have been shown to correlate with the severity of encephalopathy and adverse outcomes, suggesting their value in early diagnosis and prognosis [2][3][9]. Similarly, plasma biomarkers such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) have demonstrated predictive accuracy when aligned with abnormal MRI findings and developmental delay [3].

In addition to neuro and hepatic markers, TH appears to influence renal and cardiac biomarkers. Elevated urinary NGAL and KIM-1 levels indicate acute kidney injury in HIE, warranting close renal monitoring [4]. Cardiac troponin I (cTnI) levels also serve as indicators of myocardial injury and are linked to disease severity [5]. Other investigations have focused on integrating neuroimaging, lactate levels, and aEEG readings to refine prognostic accuracy. Advanced imaging techniques like DTI and MR spectroscopy help identify injury patterns and predict outcomes [14]. Blood gas parameters such as arterial pH and base deficit within 6 hours post-birth have also proven useful in early risk stratification [15]. Moreover, TH has shown anti-inflammatory and anti-apoptotic mechanisms at the cellular level in preclinical models, which could be optimized through adjunctive therapies [12]. The combined use of biomarkers and neurophysiological tools like aEEG enhances early diagnosis and personalized care [11][13][14][15].

3. PROPOSED METHOD

A. Biomarker Kinetics in Neonatal HIE (First-order Kinetics)

This first-order differential equation models the decline of brain injury biomarkers such as GFAP or UCHL1 in neonatal plasma following hypoxic-ischemic events and therapeutic hypothermia, aiding in evaluating injury severity and treatment response.

$$\frac{dC}{dt} = -kC \qquad (1)$$

Nomenclature :

- C: Biomarker concentration in blood (ng/mL)
- k: Elimination rate constant (s^{-1})
- t: Time (s)

B. *Lactate to Pyruvate Ratio (LPR) as Metabolic Biomarker*

Elevated LPR in brain tissue or plasma indicates anaerobic metabolism after hypoxia-ischemia. During therapeutic hypothermia, changes in LPR reflect metabolic recovery or ongoing injury in neonatal HIE.

$$LPR = \frac{[Lactate]}{[Pyruvate]} \qquad (2)$$

Nomenclature:

- $[Lactate]$: Concentration of lactate (mM)
- $[Pyruvate]$: Concentration of pyruvate (mM)

C. Blood Flow–Metabolism Coupling in Hypothermia

This equation relates cerebral blood flow changes proportionally to metabolic rate changes under hypothermia, capturing the

physiological coupling important in managing cerebral perfusion during neonatal HIE therapeutic hypothermia.

$$\frac{\Delta CBF}{CBF} = \alpha \frac{\Delta CMR}{CMR} \quad (3)$$

Nomenclature :

- CBF: Cerebral blood flow
- CMR: Cerebral metabolic rate
- α: Coupling coefficient (~1.1% decrease in CBF per 5.1% decrease in CMR)
- Δ: Change in respective parameters

D. Heat Transfer Balance During Hypothermia

This Represents the fundamental heat balance in brain tissues under therapeutic hypothermia, describing the net effect of cooling interventions on brain temperature, vital for optimizing neuroprotection in neonatal HIE.

$$Qin - Qout = \frac{dU}{dt} \quad (4)$$

Nomenclature:

- Qin: Heat entering the brain tissue (W)
- $Qout$: Heat leaving the brain tissue (W)
- $\frac{dU}{dt}$: Rate of change of internal energy of brain (W)

4. RESULT AND DISCUSSION

A. ALT and CRP Levels in HIE Infants With and Without Therapeutic Hypothermia:

Figure 3 presents a bar chart comparing hepatic biomarkers—mean alanine aminotransferase (ALT) and peak C-reactive protein (CRP) levels—in neonates with hypoxic-ischemic encephalopathy (HIE) who received therapeutic hypothermia (TH) and those who did not. The chart illustrates significantly lower ALT and CRP values in the TH group compared to the non-TH group, suggesting a hepatoprotective and anti-inflammatory effect of therapeutic hypothermia.



Figure 3: ALT and CRP Levels in HIE Infants With and Without Therapeutic Hypothermia

Specifically, the TH group had a mean ALT of 48.6 U/L and a CRP level of 11.2 mg/L, while the non-TH group had higher mean values of 72.3 U/L and 16.7 mg/L, respectively. These differences support the hypothesis that TH not only protects the brain but also mitigates systemic organ damage in HIE infants.

B. IL-6, IL-8, and NSE Levels in Mild, Moderate, and Severe HIE:

Figure 4 shows a line chart illustrating the relationship between the severity of hypoxic-ischemic encephalopathy (HIE) and the levels of IL-6, IL-8, and neuron-specific enolase (NSE) in neonates. As the severity of HIE increases from mild to severe, all three biomarkers—IL-6, IL-8, and NSE—show a clear upward trend. IL-6 levels rise from 85 pg/mL in mild HIE to 295 pg/mL in severe HIE.



Figure 4: IL-6, IL-8, and NSE Levels in Mild, Moderate, and Severe HIE

Similarly, IL-8 levels increase from 72 pg/mL in mild to 260 pg/mL in severe cases. NSE levels also increase from 18 ng/mL in mild HIE to 62 ng/mL in severe HIE. This progression highlights the potential of these biomarkers to reflect HIE severity and predict adverse neurodevelopmental outcomes.

C. Blood Lactate Levels and Seizure Burden in HIE Infants:

Figure 5 presents a scatter plot chart demonstrating the relationship between blood lactate levels and the average number of seizure episodes per day in neonates with hypoxic-ischemic encephalopathy (HIE). The plot shows three lactate categories: less than 5 mmol/L, 5–10 mmol/L, and greater than 10 mmol/L. As lactate levels increase, there is a corresponding rise in seizure burden. Infants with lactate levels below 5 mmol/L experience approximately 1.2 seizures per day, those in the 5–10 mmol/L range experience around 2.8, while those exceeding 10 mmol/L average about 5.4 seizures daily.



Figure 5: Blood Lactate Levels and Seizure Burden in HIE Infants

This scatter plot emphasizes a strong positive correlation between metabolic acidosis severity and neurological instability, suggesting lactate as a valuable prognostic marker in HIE management.

D. cTnI Levels and Clinical Outcomes in Neonates with HIE:

Figure 6 is a pie chart illustrating the distribution of clinical outcomes—mild, moderate, and severe hypoxic-ischemic encephalopathy (HIE)—based on mean cardiac troponin I (cTnI) levels and associated mortality rates. The pie slices represent the percentage of neonates within each severity category. Mild HIE, associated with the lowest cTnI level (0.12 ng/mL) and 5% mortality, occupies the smallest portion.



Fig 6: cTnI Levels and Clinical Outcomes in Neonates with HIE

Moderate HIE (cTnI 0.56 ng/mL, 18% mortality) and severe HIE (cTnI 1.42 ng/mL, 41% mortality) represent increasingly larger segments, highlighting the correlation between elevated cTnI levels and worsening clinical outcomes. This visual emphasizes the prognostic value of cTnI in assessing myocardial injury severity and predicting mortality risk in neonates with HIE.

5. CONCLUSION

In conclusion, Neonatal hypoxic-ischemic encephalopathy (HIE) remains a critical concern in neonatology due to its potential for causing severe neurological impairment or death. This study highlights how therapeutic hypothermia (TH) significantly mitigates systemic inflammation and organ damage, as reflected in reduced ALT and CRP levels, showcasing its protective role beyond the brain. The results underscore the systemic impact of HIE and the benefits of timely TH intervention.

The progressive increase in IL-6, IL-8, and NSE levels with escalating HIE severity reinforces their utility as reliable biomarkers for evaluating injury extent and predicting neurodevelopmental outcomes. Likewise, the strong correlation between rising lactate levels and seizure frequency affirms the prognostic value of metabolic markers in identifying neonates at higher neurological risk.

Finally, the association between elevated cardiac troponin I (cTnI) levels and poor clinical outcomes highlights the need for a multi-systemic biomarker approach in HIE management. Integrating biochemical, metabolic, and cardiac indicators enhances early diagnosis, monitoring, and personalized therapeutic strategies.

REFERENCES

[1] Muniraman, H. K., Donn, S. M., & Short, B. L. (2017). Hepatic biomarkers in neonates with hypoxic-ischemic encephalopathy and the effect of therapeutic hypothermia. *Journal of Perinatology*, 37(5), 539–544. https://doi.org/10.1038/jp.2016.260

[2] Chalak, L. F., Nguyen, K. A., Prempunpong, C., Heyne, R. J., & Sanchez, P. J. (2014). Early biomarkers of hypoxic-ischemic encephalopathy and the effects of therapeutic hypothermia. *Pediatric Research*, 76(1), 93–100. https://doi.org/10.1038/pr.2014.61

[3] Massaro, A. N., Bammler, T. K., MacDonald, J. W., & McKnight, R. A. (2012). Plasma biomarkers of brain injury in neonatal hypoxic-ischemic encephalopathy. *Journal of Pediatrics*, 161(4), 671–677. https://doi.org/10.1016/j.jpeds.2012.03.004

[4] Sweetman, D. U., Cleary, G., O'Donnell, C. P. F., & Molloy, E. J. (2016). Serum and urinary biomarkers of acute kidney injury in neonatal encephalopathy. *Pediatric Nephrology*, 31(4), 595–602. https://doi.org/10.1007/s00467-015-3254-2

[5] Shastri, A. T., & Sira, J. (2012). Cardiac troponin I levels in neonates with hypoxic-ischemic encephalopathy. *Indian Pediatrics*, 49(4), 297–299. https://doi.org/10.1007/s13312-012-0060-1

[6] Jacobs, S. E., Berg, M., Hunt, R., Tarnow-Mordi, W. O., Inder, T. E., & Davis, P. G. (2013). Cooling for newborns with hypoxic ischaemic encephalopathy. *Cochrane Database of Systematic Reviews*, (1), CD003311. https://doi.org/10.1002/14651858.CD003311.pub3Wikipedia

[7] Gluckman, P. D., Wyatt, J. S., Azzopardi, D., Ballard, R., Edwards, A. D., Ferriero, D. M., ... & Gunn, A. J. (2005). Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre

randomised trial. *The Lancet*, 365(9460), 663–670. https://doi.org/10.1016/S0140-6736(05)17946-XWikipedia

[8] Shankaran, S., Laptook, A. R., Ehrenkranz, R. A., Tyson, J. E., McDonald, S. A., Donovan, E. F., ... & Higgins, R. D. (2005). Whole-body hypothermia for neonates with hypoxic–ischemic encephalopathy. *New England Journal of Medicine*, 353(15), 1574–1584. https://doi.org/10.1056/NEJMcps050929

[9] Satriano, R. A., & Shapiro, S. M. (2017). Biomarkers for neonatal hypoxic-ischemic encephalopathy: past, present, and future. *Pediatric Neurology*, 77, 3–9. https://doi.org/10.1016/j.pediatrneurol.2017.08.001

[10] Heljic, S., & Avdagic, E. (2018). Blood lactate levels as a prognostic marker in neonates with hypoxic-ischemic encephalopathy. *Medical Archives*, 72(1), 20–23. https://doi.org/10.5455/medarh.2018.72.20-23

[11] Shah, D. K., Wusthoff, C. J., Clarke, P., Wyatt, J. S., & Cowan, F. M. (2018). Electroencephalography and magnetic resonance imaging in hypoxic-ischemic encephalopathy. *Seminars in Fetal and Neonatal Medicine*, 23(4), 234–241. https://doi.org/10.1016/j.siny.2018.04.002

[12] Li, L., Zhang, X., & Zhang, Y. (2020). Therapeutic hypothermia inhibits inflammation and apoptosis in a neonatal rat model of hypoxic-ischemic encephalopathy. *Brain Research*, 1727, 146547. https://doi.org/10.1016/j.brainres.2019.146547

[13] Douglas-Escobar, M., & Weiss, M. D. (2010). Biomarkers of hypoxic-ischemic encephalopathy in newborns. *Frontiers in Bioscience (Elite Edition)*, 2, 47–63. https://doi.org/10.2741/e77

[14] Wintermark, P., Hansen, A., Warfield, S. K., Dukhovny, D., Soul, J. S., & Volpe, J. J. (2014). Near-infrared spectroscopy versus magnetic resonance imaging to assess brain injury in newborns undergoing therapeutic hypothermia. *Journal of Pediatrics*, 164(4), 696–701. https://doi.org/10.1016/j.jpeds.2013.11.027

[15] Baserga, M. C., & Bauer, C. R. (2015). Early blood gas predictors of hypoxic-ischemic encephalopathy in term infants. *Journal of Perinatology*, 35(7), 529–533. https://doi.org/10.1038/jp.2015.17

..